Abstract-Advanced atherosclerosis is often associated with dystrophic calcification, which may contribute to plaque rupture and thrombosis. In this work, the localization and association of the noncollagenous bone matrix proteins osteonectin, osteopontin, and osteocalcin with calcification, lipoproteins, thrombus/hemorrhage (T/H), and matrix metalloproteinases (MMPs) in human carotid arteries from endarterectomy samples have been determined. According to the recent American Heart Association classification, 6 of the advanced lesions studied were type V (fibroatheroma) and 16 type VI (complicated 4 and ex vivo 5 detection of calcium deposits in coronary arteries, have shown that calcification is correlated with atherosclerotic plaque burden and that noninvasive detection of calcification may have predictive value in the development of subsequent coronary events. 5 The molecular determinants regulating extracellular matrix calcification have yet to be identified. Recent studies have shown that noncollagenous bone matrix proteins such as osteonectin, osteocalcin, and osteopontin are also found in atherosclerotic vessels and may regulate dystrophic calcification. For example, osteonectin (SPARC) has been identified in vessel wall cells 6 and platelets 7 and participates in the regulation of bone mineralization, 8 cell migration/proliferation, 9 and remodeling of extracellular matrix. 10 -12 Recently, it has been shown that osteonectin binds to plasminogen, 13 increases its activation and binding to collagen, 13 and induces the expression of type 1 plasminogen activator inhibitor in endothelial cells (ECs). 14 That suggests a role for osteonectin in both the degradation of extracellular matrix and the regulation of fibrinolysis. Moreover, osteonectin upregulates the expression of matrix metalloproteinases (MMPs) in cultured fibroblasts. 15 Previous studies have implicated MMPs in destabilization and rupture of atherosclerotic plaques, 16 -19 and we recently showed that both fibrinogen and cross-linked fibrin, proteins known to be associated with both early and complicated plaques, can be degraded by MMP-2, 
D
ystrophic mineralization of the arterial wall increases the risk of myocardial infarction and ischemia in peripheral vascular lesions. 1 More than 80% of coronary lesions are calcified, 2 and calcium deposits are often associated with unesterified cholesterol. 3 Two very recent studies, on the in vivo 4 and ex vivo 5 detection of calcium deposits in coronary arteries, have shown that calcification is correlated with atherosclerotic plaque burden and that noninvasive detection of calcification may have predictive value in the development of subsequent coronary events. 5 The molecular determinants regulating extracellular matrix calcification have yet to be identified. Recent studies have shown that noncollagenous bone matrix proteins such as osteonectin, osteocalcin, and osteopontin are also found in atherosclerotic vessels and may regulate dystrophic calcification. For example, osteonectin (SPARC) has been identified in vessel wall cells 6 and platelets 7 and participates in the regulation of bone mineralization, 8 cell migration/proliferation, 9 and remodeling of extracellular matrix. 10 -12 Recently, it has been shown that osteonectin binds to plasminogen, 13 increases its activation and binding to collagen, 13 and induces the expression of type 1 plasminogen activator inhibitor in endothelial cells (ECs). 14 That suggests a role for osteonectin in both the degradation of extracellular matrix and the regulation of fibrinolysis. Moreover, osteonectin upregulates the expression of matrix metalloproteinases (MMPs) in cultured fibroblasts. 15 Previous studies have implicated MMPs in destabilization and rupture of atherosclerotic plaques, 16 -19 and we recently showed that both fibrinogen and cross-linked fibrin, proteins known to be associated with both early and complicated plaques, can be degraded by MMP-2, MMP-3, 20 and MMP-7. 21 Osteopontin is synthesized by most vascular cells, 22 and its distribution in coronary arteries has been shown to be associated mainly with macrophages 23 and foam cells 24 in the lipid core, adjacent to 23 or colocalized with 25 the calcification front and in calcified areas in carotid arteries. 26 Expression of both osteopontin and osteonectin was previously studied in a limited number of aortas (8 autopsy cases). 6 Osteopontin, together with osteocalcin and bone syaloprotein II, is also found in platelets. [27] [28] [29] Osteocalcin is the most abundant of the noncollagenous proteins of bone produced by osteoblasts that promotes adhesion and chemotaxis in osteoclasts, but it has not been described in other cells. 30 Additionally, although osteocalcin has been extracted from atherosclerotic plaques, 31,32 data on its distribution are not available. Recent studies have shown that bovine osteoblast-like vascular cells can synthesize osteocalcin in vitro. 33 In this study, the cellular and extracellular localization of bone matrix proteins in clinical carotid artery atherosclerosis suggests the existence of a potentially important and complex interaction among noncollagenous bone proteins, calcific deposits, plaque growth, and matrix degradation that might further contribute to plaque disruption and thrombosis.
Methods
Human carotid endarterectomy specimens were collected at surgery and immediately rinsed in Tris-buffered saline containing benzamidine and aprotinin as described, 34 fixed in Histochoice (Amresco), and subsequently embedded in paraffin. All samples, with the exception of 1 (No. 7641), were embedded undecalcified, as in previous studies. 34 The use of undecalcified tissue allows observation of the earliest deposits, including cell association, therefore offering the possibility of linking descriptive morphology to mechanism. 35 Sample No. 7641 was heavily calcified and brittle and therefore was decalcified by chelation. 36 It has been shown that such procedure maintains the antigenicity of monoclonal antibody (MoAb) MPIIIB10 1 to osteopontin, 37 also used in this study.
Lesions were classified according to American Heart Association criteria. 38 Six lesions were type V (defined as type Va: fibroatheroma with lipid core and fibrotic layer; type Vb: multiple lipid cores and fibrotic layers; or type Vc: mainly calcific, or mainly fibrotic), and 16 were type VI (defined as complicated lesion, with surface defect, hematoma, hemorrhage, and/or thrombotic deposits). Tissues used as controls (for antibodies to osteonectin and osteocalcin only, because all other antibodies used in the study were previously characterized) included normal arteries 34 and normal-term human placenta. 39 Fresh specimens were processed as above. All samples were part of different Institutional Review Board protocols approved by our own and other collaborating institutions.
Immunohistochemistry
Previously characterized MoAbs and polyclonal antibodies were used with the avidin-biotin complex immunoperoxidase technique, essentially as described, 34, 39 with use of the Vectastain Elite ABC kit (Vector Laboratories Inc). The end product of the reaction with diaminobenzidine forms an insoluble brown precipitate. The MoAbs used were as follows: IIIA 3 A 8 (10 g/mL) to osteonectin and G12 (2 g/mL) to osteocalcin. 40 In normal vessels and placental tissue, osteonectin was detected in ECs, smooth muscle cells (SMCs), and decidua cells as previously described. 11 Osteocalcin was not detected in any cell type.
In previous studies, the 2 antibodies used to detect osteopontin, MPIIIB10 1 and antiserum LF-7 (Dr Larry W. Fisher, National Institutes of Health, Bethesda, Md), showed a different distribution. Therefore, in this study we used both antibodies. MoAb MPIIIB10 1 (clone culture fluid 1/20) to osteopontin was obtained from Dr Karen Jansen, Developmental Studies Hybridoma Bank, Department of Biological Sciences, University of Iowa, Iowa City, 41 and rabbit antisera LF-123 (to the recombinant carboxyl half of human osteopontin, 1/8000) and LF-124 (to the recombinant amino half of human osteopontin, 1/8000) were a kind gift of Dr Larry W. Fisher. 42, 43 Because the 2 antibodies reacted similarly in serial sections from the same vessel specimens, LF-123 only was used throughout the study.
MoAb 18C6 to fibrinogen/fibrin I, MoAb T2G1 to fibrin II, and MoAb GC4 to fibrin(ogen) degradation product fragments D and D-dimer have been previously described. 34, 39 To detect intact fibrinogen, we used a recently developed MoAb (FPA 19/7), specific for the human fibrinopeptide A sequence (A␣1-16), which reacts significantly better with intact fibrinogen than it does with the free peptide. 44 MoAbs to human matrix MMP-2 (gelatinase A) and MMP-3 (stromelysin 1, 1 to 3 g/mL) were purchased from Oncogene Science. Goat antisera to human apoAI, apoE, and apoB were generously provided by Dr Paul S. Roheim, Louisiana State Medical Center, New Orleans, and to Lp(a) were kindly provided by Dr Angelo Scanu, University of Chicago, Chicago, Ill. MoAbs HAM56 and HHF35 (Enzo Diagnostics) were used to identify macrophages and SMC populations, respectively. Ulex europaeus agglutinin and rabbit antiserum to ulex europaeus lectin (Dako Corp) were used to identify ECs. A selected number of samples were double-stained with MoAb IIIA 3 A 8 (osteonectin) and alternatively with antibodies to macrophages, SMCs, and ECs to identify in which cells osteonectin was cytoplasmic. The Vector VIP substrate kit produces a purple precipitate that is distinguishable from the brown precipitate produced by diaminobenzidine.) All samples were routinely stained with HPS (hematoxylin, phloxine B, and safranin O) and with von Kossa's stain, which detects the presence of calcium phosphates in mineralized tissues. 45 
Results

Calcification in Endarterectomy Specimens
Calcium deposits, identified by von Kossa's reaction for calcium phosphate, were present in 18 of 22 samples (3 of 6 type V and 15 of 16 type VI). These deposits were distinguished as large masses of calcification, mainly central to the lesion (7 samples) or as smaller clusters of needle-shaped apatite crystals (21 samples). 46 
Distribution of Bone Matrix Proteins, Apolipoproteins, Fibrin(ogen), and Calcification
All of these antigens were present in both type V and type VI lesions, with a cellular and/or extracellular localization. Therefore, a table summarizing all scores would convey little information. Similarly, because endarterectomy samples are only an incomplete fraction of the atherosclerotic plaque, a traditional morphometric analysis could not be completed. For the same reason, the site of plaque rupture was rarely identified. In fact, it is possible that during the course of endarterectomy, the actual site of plaque rupture is not excised. However, whereas all type V lesions were of types Vb and Vc (ie, there were no type Va "vulnerable" plaques), in 12 of 16 type VI lesions (75%), a central core with calcification, hemorrhage, thrombus, and/or cholesterol crystals could be identified. These data are summarized in Figure  1 as the colocalization of calcium deposits, cholesterol crystals, and thrombus/hemorrhage (T/H) identified by their major protein components.
The areas immunostained with MoAb T2G1 have been subdivided as areas of either organizing thrombus and intraplaque hemorrhage (ie, T/H) or fibrin II. Fibrin II is used to indicate fibrin that is localized in parallel bundles and threads in the intima, subintima, and media and in association with vascular wall cells (mainly macrophages and macrophage-derived foam cells) 34 as distinct from fibrin that appears colocalized with T/H.
Type V Lesions
Fibrinogen/fibrin I was diffuse from the lumen to the intact portion of the media (Figure 2a ), similar to apoB (Figure 2e ). Fibrin II, fragment D/D-dimer, and Lp(a) colocalized in the intima and neointima in small focal deposits, along the calcification front, and were associated with macrophages, foam cells, and SMCs (Figures 2b through 2f) . Osteonectin was cytoplasmic in ECs, SMCs, macrophages, and macrophage-derived foam cells, as identified by their respective antibodies (Figures 2d and 2g) . Small calcifications, detected with von Kossa's stain, were present in most lesions, along the calcification front and in degenerative areas (Figure 2h ). Osteopontin was cytoplasmic in macrophages and SMCs in the intima and neointima (Figures 3a and 3b ) and along the calcification front (with antiserum LF-123 only; Figure 3a ). MMP-3 was cytoplasmic in most cells: in the extracellular matrix, along the calcification front, and in the fibrotic portion of the lesions in a granular pattern (Figure 3c ). Slightly diffuse staining for MMP-2 was observed at the calcification front only (Figure 3d ).
Type VI Lesions
Calcification was present in all but 1 type VI lesion studied. A calcified lipid core and smaller areas of sparse calcification are shown with von Kossa's stain (Figures 4a and 5a) . Fibrinogen/fibrin I was distributed along and within the intima and in the plaque shoulder associated with macrophages, SMCs, cholesterol crystals, and calcium deposits (Figures 4b and 5b) . Fibrin II (Figures 4c and 5c ) and fragment D/D-dimer (Figures 4d and 5d) showed similar associations, were more focal, and also colocalized with areas of intramural T/H. In addition to the MoAbs to fibrin(ogen) used in our previous studies, we recently developed a MoAb, FPA 19/7, that reacts only with intact fibrinogen and is specifically directed to the intact amino terminus of the A␣-chain. Immunolocalization of fibrinogen with intact A␣-chain colocalized with that of intact fibrinogen B␤-chain (MoAb I8C6) but usually involved a smaller area (not shown).
The distribution of apoB extended from the normal portion of the media into the lipid, calcified core (Figure 4e ), similar to that of apoAI and apoE (not shown). ApoB colocalized with fibrinogen, fibrin II, and fragment D/D-dimer in the intima, plaque shoulder, and lipid core (Figures 4b through  4f) . The distribution of Lp(a) was different from that of the other apolipoproteins. Lp(a) was mainly localized along the margins of the lipid, calcified core and was colocalized extracellularly with fibrin II and fragment D/D-dimer along the intima, in the subintima, and in association with macrophages (Figures 4e and 5e) .
Fibrinogen, fibrin II, and fragment D/D-dimer colocalized with osteonectin, osteopontin, osteocalcin, and apolipoproteins in the calcified core (Figures 4b through 4d, 4g through 4i, and 5b through 5h). Osteocalcin occurred as both large calcium deposits (Figures 4i and 5g ) and as smaller calcification foci (Figure 5g ), similar to osteonectin and osteopontin (Figures 4g, 4h, 5f , and 5h). Osteopontin colocalized in the plaque shoulder with fibrinogen, fibrin II, fragment D/Ddimer, Lp(a), apoB, and MMP-3 ( Figure 4h) .
A higher-magnification view of the calcification front area in this lesion (demarcated area in Figure 5i ) showed cytoplasmic colocalization of osteonectin, osteopontin, and MMP-3 in macrophage, foam cells, and calcium deposits (Figures 6a  through 6e) . Osteopontin was seen mainly in macrophages, similar to MMP-2 (Figures 6b and 6d ). MMP-3 was cytoplasmic in most cells (Figure 6c ), similar to osteonectin and osteopontin, and colocalized with fibrin II, apolipoproteins, and calcium deposits (Figures 4j and 6c ). MMP-2 was heterogeneously localized in various cell types and, when in association with calcium deposits, was found mainly at the calcification front (Figures 4l and 6d) .
In summary (Figure 1) , osteonectin was associated with calcium deposits in 33% of type V and in 88% of type VI lesions. Osteopontin (antiserum LF-123) colocalized with calcium phosphate crystals in 50% of type V lesions and 94% of type VI lesions. No association of osteopontin with calcium deposits was detected with MoAb MPIIIB10 1 . Osteocalcin was detected in large calcium deposits only, in 17% of type V and in 38% of type VI lesions. MMP-3 was present in 50% of type V lesions and in 93.6% of type VI lesions, whereas MMP-2 was in 50% of type V and in 53% of type VI lesions. 
Discussion
Role of Bone-Related, Noncollagenous Proteins in Atherosclerosis Calcification
This work has identified the cellular and extracellular localization of the major bone proteins osteonectin, osteocalcin, and osteopontin with calcium deposits in undecalcified carotid atherosclerotic plaques to determine their association with major protein components of atherosclerotic plaques, including apolipoproteins, fibrin(ogen)-related antigens, and MMPs. As shown in Figure 1 , all antigens studied were increasingly associated with calcification, progressing from type V to type VI lesions, including the bone matrix proteins osteonectin, osteopontin, and osteocalcin. MMP-3 also strongly colocalized with calcium deposits, whereas MMP-2 seemed to be less associated with it.
Previous work showed that a number of bone-related, noncollagenous matrix proteins, including osteonectin, osteocalcin, and osteopontin, may also play a role in plaque calcification by regulating the growth of hydroxyapatite crystals. 47 In-vitro studies have shown that these proteins also function in cell migration and tissue healing. 9, 30, 48 However, their role in the regulation of bone mineralization (ie, favoring or inhibiting bone mineralization) has not yet been completely elucidated. 30 In fact, osteocalcin-knockout mice show increased bone formation. 49 Vascular SMCs have the ability to calcify in vitro, expressing higher levels of matrix Gla protein and low levels of osteopontin. 50 However, mice lacking matrix Gla protein incur spontaneous calcification of arteries and cartilage. 51 Surprisingly, mice lacking osteoprotegerin, a protein that regulates bone resorption, also develop arterial calcification. 52 Osteonectin has been shown to promote binding of calcium to collagen, 53 thus suggesting a role in promoting calcium deposition. Additional work has indicated that osteonectin, and to a lesser extent osteocalcin, could inhibit hydroxyapatite crystal formation. 54 This role seems to prevent excessive mineralization in bone. Osteonectin and osteocalcin are detectable in normal plasma and serum 40, 55 and together with osteopontin are also present in human platelets. 7,27,28 The results on the distribution of these 3 bone-related proteins, osteonectin, osteopontin, and osteocalcin, in carotid artery atherosclerotic plaques have shown that they colocalize with large calcium deposits in clinically significant type V and type VI lesions. Moreover, osteonectin and osteopontin colocalized with areas of small calcification, with and without degeneration, 56 and were cytoplasmic in most cells, whereas osteocalcin was not detected in any cell type. Previous studies localized osteonectin in arterial medial SMCs, 6 in tumoral and vascular cells, 11 and in a variety of other cell types in addition to mineralized tissue. 8, 57 In all type V and VI lesions, osteonectin was cytoplasmic in ECs, macrophages, foam cells, selected SMCs, and a few unidentified cells, possibly pericyte-like cells. These have also been shown to synthesize osteopontin and osteonectin in vitro 33 and bring about local formation of calcification nodules. 58, 59 Antibodies to osteopontin, MoAb MPIIIB10 1 23,48 and antiserum LF-7, 25, 26, 47 were used in previous studies and showed a different distribution. In our study, MoAb MPIIIB101 was mainly associated with macrophages, 23, 48 although both ECs and SMCs stained lightly. Antiserum LF-123 (raised against the carboxy-terminal portion of human osteonectin, whereas LF-7 was raised against full-length osteonectin) exhibited a stronger association with calcium deposits and gave a granular staining pattern to the extracellular matrix, in addition to the macrophage staining as shown by others. 25, 26, 47 Results obtained with both antibodies can explain the cellular versus cellular/extracellular localization shown in previous work. 23, 25, 26, 47, 48 In those studies and in this work, larger numbers of cells containing osteopontin were observed in atherosclerotic versus normal vessels.
This study confirms and extends previous data on bone matrix proteins in atherosclerotic plaques and suggests that more than 1 cell type secretes several of these proteins (bone morphogenetic protein-2a, osteopontin, osteonectin, and matrix Gla protein) and thereby may participate in the calcification process that occurs in the development of atherosclerosis. 6, 23, 25, 26, 60 Although osteocalcin has been extracted from atherosclerotic plaques, 31, 32 we did not detect it associated with any cell types in any of the atheromas examined. Because in this work we have shown that osteocalcin colocalized with fibrin II/calcium deposits, it might be derived from plasma and/or platelets. The presence of osteonectin, osteocalcin, and osteopontin in plasma and platelets may serve as a concentrated source of noncollagenous matrix proteins that can contribute to vessel wall calcification after a thrombotic or hemorrhagic event. 61 
Relationships Among Lipids, Apolipoproteins, and Thrombosis
The distribution of apolipoproteins and fibrin(ogen) in these lesions was similar to that in previous studies. 34, 62 ApoAI, B, and E codistributed with fibrin II and cholesterol crystal deposits. Lp(a) was observed mainly at the margins of the cholesterol crystal deposits. In the intima and subintima, Lp(a) was closer to the lumen, similar to what was formerly described for the aorta and coronary arteries, [63] [64] [65] and often colocalized with fibrin II deposits. That might interfere with the assembly of fibrinolytic proteins on the fibrin surfaces, thereby hampering fibrinolysis. 66, 67 The main morphological difference between type V and type VI lesions was that in all type VI lesions, there was either intraplaque hemorrhage or mural thrombus. However, in all type V and VI lesions, there was also cell-associated or extracellular fibrin II. In type V lesions, fibrin II was localized in bundles and threads in the intima and subintima, associated with SMCs and macrophages, possibly due to the localized formation of intraplaque fibrin as previously described 39 and more recently shown. 68 In addition, with a new antibody to the intact amino terminus of the A␣-chain of fibrinogen that was not available in previous studies, we confirmed that part of the fibrin(ogen)-related antigen was intact, possibly transglutaminase-cross-linked fibrinogen. 69 Bone proteins such as osteonectin and osteopontin can be cross-linked by tissue transglutaminase and factor XIIIa. 70 These proteins might become cross-linked to fibrin(ogen) in the progression of an atherosclerotic plaque, particularly during or after formation of intraplaque hemorrhage or thrombus, where they are abundant and factor XIII is in its active form (factor XIIIa). Additionally, because fibronectin is present in both the vessel wall and the clot, bone proteins might be indirectly bound to fibrinogen via fibronectin cross-linking and therefore might participate in the formation of matrix that will evolve in dystrophic calcification.
Role of Calcification in Plaque Progression and Instability: Possible Upregulation of MMPs
No major differences in cellularity were observed between calcified and noncalcified lesions. Both in the current and previous studies, calcium hydroxyapatite crystals were seen within organizing thrombi. Several factors likely play a role in the calcification of the vessel wall, including (1) calcification of thrombus; (2) calcification of degenerate(d) SMCs and macrophages; (3) local synthesis of calcification proteins; and (4) local bone neoformation, such as that seen occasionally in atherosclerotic vessels.
The main questions about bone matrix proteins are how, when, and which of these proteins favors or limits the calcification process. Because osteonectin has been shown to upregulate MMPs in cultured fibroblasts, 15 it might be suggested that osteonectin can upregulate the synthesis of MMPs in both SMCs and macrophages in atherosclerotic plaques. Therefore, calcification and degradation of the extracellular matrix in atherosclerotic plaques might be synergistically regulated.
Recently, we have shown that MMP-2 can degrade fibrinogen and that MMP-3 and MMP-7 can degrade both fibrinogen and cross-linked fibrin. 20, 21 Different classes of MMPs might exert different roles in plaque progression and rupture according to their preferred substrates. The possible role of such a mechanism in atherosclerosis requires further investigation.
Early work suggested that lipids might be involved in biological mineral formation. [71] [72] [73] More recently, it has been found that mineral deposits in the human aorta contain a relatively high concentration of protein (12% to 18%), in addition to calcium apatite and calcium carbonate, and most likely include some glycoprotein. 74 Some of these may be bone proteins such as osteonectin and osteopontin, which were identified in the atherosclerotic lesions examined in the present study.
Recently, it was hypothesized that calcium deposits form after plaque rupture as part of complicated lesions, a phenomenon that is rarely seen in small, "soft," cholesterol-rich plaques. In our study, 69% of complicated type VI lesions showed a central core that was necrotic, calcified, thrombosed, and/or hemorrhaged and that contained bone proteins, apolipoproteins, fibrin, and MMPs (particularly MMP-3), suggesting that these lesions were derived from type Va lesions (according to the recent American Heart Association classification).
In conclusion, the present study establishes the colocalization of dystrophic calcification with intraplaque T/H, cholesterol, and their corresponding protein components in human carotid arterial atherosclerosis. These results suggest that intraplaque T/H might contribute to arterial calcification as a source of osteocalcin and that bone matrix proteins, apolipoproteins, fibrin(ogen), and MMPs might interact in the formation of dystrophic calcification, progression, and complications of atherosclerotic lesions. The results of this study also suggest potential targets for early and noninvasive detection and characterization of lesions.
